Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is GenFleet Therapeutics (Shanghai) PS Ratio?
GenFleet Therapeutics (Shanghai)HAM:Y3L -2.80%19 PS Ratio is 64.80 as of Aug. 04, 2026, which is 11% below its 10-year median of 72.56. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 931 Biotechnology companies, GenFleet Therapeutics (Shanghai) ranks worse than 82.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, GenFleet Therapeutics (Shanghai)'s share price is €2.916.
GenFleet Therapeutics (Shanghai)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05. Hence, GenFleet Therapeutics (Shanghai)'s PS Ratio for today is 64.80.
GenFleet Therapeutics (Shanghai) (HAM:Y3L) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
GenFleet Therapeutics (Shanghai) PS Ratio Related Terms
GenFleet Therapeutics (Shanghai) PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) PS Ratio Chart
GenFleet Therapeutics (Shanghai) Annual Data
Trend
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
49.01
GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PS Ratio
0.00
0.00
0.00
0.00
49.01
HAM:Y3L vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenFleet Therapeutics (Shanghai) PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s PS Ratio distribution charts can be found below:
* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s PS Ratio falls into.
GenFleet Therapeutics (Shanghai) PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
GenFleet Therapeutics (Shanghai)'s Share Price of today is €2.916.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. GenFleet Therapeutics (Shanghai)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a PS Ratio of 64.80 as of Aug. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. This is 11% below median its historical median of 72.56. Over the past decade, GenFleet Therapeutics (Shanghai)'s PS Ratio has ranged from 45.97 to 117.93. According to the industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #767 out of 931 companies in the Biotechnology industry, placing it in the top 82.4%.
Is GenFleet Therapeutics (Shanghai)'s PS Ratio too high?
GenFleet Therapeutics (Shanghai)'s current PS Ratio of 64.80 is 11% below median its 10-year median of 72.56. Over the past 10 years, this metric has ranged from a low of 45.97 to a high of 117.93. The Biotechnology industry median PS Ratio is 8.91. GenFleet Therapeutics (Shanghai)'s value of 64.80 is 627.3% above this industry median. Based on the distribution chart, GenFleet Therapeutics (Shanghai) ranks #767 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #767 out of 931 companies for PS Ratio. This places GenFleet Therapeutics (Shanghai) in the lower half of its industry. The industry median PS Ratio is 8.91. GenFleet Therapeutics (Shanghai)'s value of 64.80 is 627.3% above this benchmark. Historically, GenFleet Therapeutics (Shanghai)'s own PS Ratio has ranged from 45.97 to 117.93 over the past decade. While the company's 10-year median is 72.56 vs. the industry median of 8.91, GenFleet Therapeutics (Shanghai) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 8.91, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenFleet Therapeutics (Shanghai)'s current PS Ratio of 64.80 is 627.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. For the Biotechnology industry, the median PS Ratio is 8.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenFleet Therapeutics (Shanghai)'s current PS Ratio is 64.80, which is 11% below median its own 10-year median of 72.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current PS Ratio of 64.80. The current PS Ratio is 64.80, which is 11% below median its 10-year median of 72.56 and 627.3% above the Biotechnology industry median of 8.91. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current PS Ratio is 64.80 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score
Get the complete analysis for HAM:Y3L
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Y3L has been successfully added to your 
